Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRXNASDAQ:KYMRNASDAQ:REPLNASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$3.07-3.8%$2.63$1.83▼$7.63$2.71B0.146.05 million shs16.71 million shsKYMRKymera Therapeutics$46.96-0.7%$32.72$19.45▼$53.27$3.06B2.07616,844 shs464,322 shsREPLReplimune Group$9.78-1.1%$8.60$6.44▼$17.00$753.91M0.63901,349 shs680,187 shsRLAYRelay Therapeutics$3.22-6.7%$2.96$1.78▼$10.72$552.05M1.592.08 million shs2.02 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-3.76%-2.54%+23.29%+6.97%-45.18%KYMRKymera Therapeutics-0.70%-1.39%+57.85%+36.63%+35.72%REPLReplimune Group-1.11%-5.78%+39.51%-16.05%+10.88%RLAYRelay Therapeutics-6.67%-4.17%+16.25%-12.02%-58.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBRXImmunityBio2.5184 of 5 stars3.62.00.00.02.81.70.6KYMRKymera Therapeutics3.1171 of 5 stars4.53.00.00.02.41.70.0REPLReplimune Group4.517 of 5 stars3.63.00.04.53.82.50.6RLAYRelay Therapeutics2.2046 of 5 stars3.42.00.00.01.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 3.20Buy$12.25299.02% UpsideKYMRKymera Therapeutics 3.00Buy$59.8227.39% UpsideREPLReplimune Group 3.14Buy$20.83113.02% UpsideRLAYRelay Therapeutics 2.83Moderate Buy$17.67448.65% UpsideCurrent Analyst Ratings BreakdownLatest RLAY, IBRX, KYMR, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.006/2/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$51.006/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/28/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/20/2025KYMRKymera TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$31.22M86.79N/AN/A($0.88) per share-3.49KYMRKymera Therapeutics$58.89M51.93N/AN/A$7.12 per share6.60REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ARLAYRelay Therapeutics$7.68M71.89N/AN/A$5.90 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%8/11/2025 (Estimated)KYMRKymera Therapeutics-$146.96M-$3.10N/AN/AN/A-191.26%-24.96%-20.27%8/6/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)RLAYRelay Therapeutics-$341.97M-$2.23N/AN/AN/AN/A-45.75%-40.75%8/5/2025 (Estimated)Latest RLAY, IBRX, KYMR, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A2.682.64KYMRKymera TherapeuticsN/A8.558.55REPLReplimune Group0.1411.4311.43RLAYRelay TherapeuticsN/A18.4218.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%KYMRKymera TherapeuticsN/AREPLReplimune Group92.53%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio76.79%KYMRKymera Therapeutics16.01%REPLReplimune Group8.80%RLAYRelay Therapeutics4.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio590882.62 million115.67 millionOptionableKYMRKymera Therapeutics17065.12 million54.52 millionOptionableREPLReplimune Group21077.09 million70.24 millionOptionableRLAYRelay Therapeutics330171.45 million160.15 millionOptionableRLAY, IBRX, KYMR, and REPL HeadlinesRecent News About These CompaniesRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Here's What HappenedJune 13 at 1:26 PM | marketbeat.comRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of DirectorsJune 11 at 4:15 PM | globenewswire.comRelay Therapeutics (NASDAQ:RLAY) Trading 6.7% Higher - What's Next?June 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Growth in Short InterestJune 5, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DEJune 4, 2025 | marketbeat.comSquarepoint Ops LLC Increases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comNuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comJane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comRelay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast CancerJune 2, 2025 | msn.comRelay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025June 2, 2025 | globenewswire.comTwo Sigma Investments LP Sells 199,482 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)May 31, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Up 5.1% - Here's What HappenedMay 30, 2025 | marketbeat.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 29, 2025 | globenewswire.comRelay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal yearMay 29, 2025 | investing.comVoloridge Investment Management LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)May 29, 2025 | marketbeat.comMan Group plc Buys Shares of 173,605 Relay Therapeutics, Inc. (NASDAQ:RLAY)May 27, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Millennium Management LLCMay 26, 2025 | marketbeat.comNorthern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)May 24, 2025 | marketbeat.comWhat Makes Relay Therapeutics (RLAY) a New Buy StockMay 23, 2025 | zacks.comBNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY)May 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksRLAY, IBRX, KYMR, and REPL Company DescriptionsImmunityBio NASDAQ:IBRX$3.07 -0.12 (-3.76%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.04 -0.03 (-1.14%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Kymera Therapeutics NASDAQ:KYMR$46.96 -0.33 (-0.70%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$46.54 -0.42 (-0.90%) As of 06/13/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Replimune Group NASDAQ:REPL$9.78 -0.11 (-1.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.88 +0.10 (+0.97%) As of 06/13/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Relay Therapeutics NASDAQ:RLAY$3.22 -0.23 (-6.67%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.26 +0.04 (+1.21%) As of 06/13/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
